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ABSTRACT The adult mammalian brain comprises many
functionally distinct neuronal types, which are generated
during development as a result of a coordinated signaling
cascade that drives neuroblasts from proliferation into dif-
ferentiation. We investigated whether and how ShcA adaptor
proteins, which are known to function as initiators of the Ras
signaling cascade in various nonneuronal systems where they
have been considered to be expressed ubiquitously, are in-
volved in the proliferative and differentiative phases of the
developing brain. We found that in the forebrain expression
and activation of ShcA proteins were strictly regulated during
embryonic development, both temporally and spatially. The
mRNAs encoded by the ShcA gene were expressed exclusively
within an area to which active proliferation of immature
neuroblasts was confined, the ventricular zone. In postnatal
and adult brain, ShcA mRNAs and proteins were present only
faintly. In the adult olfactory epithelium, in which neuronal
cell renewal occurs throughout life, ShcA remained strongly
expressed. These phenomena were peculiar to ShcA, since
Grb2 adaptor protein remained expressed at constant level
throughout development. The embryonically expressed ShcA
proteins were functionally active, since p52ShcA became phos-
phorylated on tyrosine and associated with Grb2 following
intraventricular injection of epidermal growth factor in the
embryonic brain. Our data indicate that, through an orderly
pattern of expression, ShcA gene products may play a role in
the control of the switch between proliferation and differen-
tiation of brain neuroblasts.
During mammalian neurogenesis, a temporally controlled and
spatially localized availability of mitogenic and differentiative
polypeptides and their corresponding receptors have been
implicated in the series of events that ultimately lead prolif-
erating neuroblasts to assume a terminally differentiated phe-
notype (1–3).
Many of the polypeptide growth factors known thus far exert
their effects by interacting with cell surface receptors that
contain tyrosine kinase (TK) domains and whose stimulation
results in activation of the Ras-mitogen-activated protein
kinase transduction pathway (4–6). The events upstream of
Ras activation have recently been characterized for various
growth factor receptors and have been shown to involve the
recruitment of Grb2, a 23-kDa adaptor protein, and the
guanine nucleotide release protein, Sos, by the activated
receptors (7–10), ultimately leading to stimulation of the
mitogen-activated protein kinase pathway (11, 12). Shc (from
Src homologous and collagen) is another molecule involved in
Ras activation (13). Indirect biochemical and functional evi-
dence indicates that when a receptor such as that for epidermal
growth factor (EGF) is activated, Shc adaptor protein rapidly
binds to a specific phosphotyrosine on the stimulated receptor,
becomes phosphorylated on Tyr-317 (13), and subsequently
forms stable complexes with Grb2. Within this model of
activation of the Ras pathway, following receptor stimulation,
the constitutive complex Grb2–Sos is translocated from the
cytosol to the membrane by interaction with the activated Shc,
thereby leading to p21ras activation (14). Shc protein is also
known to be involved in signaling from surface receptors
devoid of intrinsic TK activity, probably through the recruit-
ment of cytoplasmic TKs (15–19).
The Shc gene, recently renamed ShcA, encodes three pro-
teins of 46 (p46shcA), 52 (p52shcA), and 66 (p66shcA) kDa, each
containing an SH2–phosphotyrosine binding domain (20), a
central glycine- and proline-rich region (collagen homologous
region 1, CH1) (20), and a novel phosphotyrosine binding site
named the PTByPID domain (21–23). These domains are
involved in multiple proteinyprotein interactions. Thus far,
p46shcA and p52shcA isoforms, which originate from a different
translation initiation site, were found to be expressed ubiqui-
tously when considering cells of nonneuronal origin. These two
proteins are indeed present and activated in fibroblasts, hepa-
tocytes, and different immature and mature cells (i.e., T
lymphocytes) of the hematopoietic system (20, 24–28). p66shcA
protein is a less well-characterized molecule, expressed from a
distinct transcript that is absent in some hematopoietic cells
(20). Analyses of ShcA proteins functions have demonstrated
their recruitment by various different activated receptors,
including the EGF receptor (20, 24–28). ShcA proteins have
oncogenic properties, because overexpression of p46shcA and
p52shcA induces transformation in fibroblasts (20) and Ras-
dependent differentiation in PC12 cells (29). Furthermore, in
a recent report from Migliaccio et al. (30), p52yp46shcA pro-
teins were found to activate transcription from the c-fos
promoter. On the contrary, p66shcA is not capable of activating
this same promoter and does not induce transformation in
fibroblasts (30). The functional relevance of the ShcA gene is
underscored by its conservation throughout vertebrate evolu-
tion (31). When considered together, these data indicate that
ShcA proteins participate in a signaling pathway of fundamen-
tal significance for many mammalian cell types. Recently, two
new genes have been identified that encode for two Shc
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proteins, termed ShcBySli and ShcCyRai, which have been
found to be particularly enriched in the adult mouse brain (32,
33). Although ShcA-driven effector systems have been well
investigated in nonneuronal cells, a role during neurogenesis
has not been considered thus far.
MATERIALS AND METHODS
Animals. Sprague–Dawley pregnant rats of 14, 15, and 18
gestational days, neonates, and adult animals were obtained
from Charles River Breeding Laboratories. Outbred CD-1
female mice (Charles River Breeding Laboratories) were used
for the in situ analysis.
Primary Cultures. Neuronal cultures were prepared from
the embryonic day (E) 14 rat striatum primordia as described
(34). Briefly, mechanically dissociated cells were plated onto
polyornithine-coated 60-mm tissue culture dishes at a density
of 3 3 105 cells per cm2. Cells were allowed to differentiate by
growing them in serum-free medium (SFM) for different
periods of time in vitro in a humidified incubator with 95%
airy5% CO2. Cultured cells were rinsed three times in PBS and
then lysed in lysis buffer (600 ml per plate). The collected
material was handled as described below.
Antibodies. Rabbit polyclonal antibody against ShcA iso-
forms was used at a ratio of 1:2,500 (Upstate Biotechnology,
Lake Placid, NY). Anti-ShcA mAb derived from ascitic f luid
(provided by P. G. Pelicci, Istituto Europeo di Oncologia,
Milan) was applied at 1:3. mAb against Grb2 (Upstate Bio-
technology) was applied at 1:1,000. mAb against a-tubulin
(Sigma) was used at 1:5,000 dilution (this antibody recognizes
all different isotypes of a-tubulin present in the rat brain).
mAb against phosphotyrosines (Upstate Biotechnology) was
applied at 1:1,000. Secondary antibodies (goat anti-rabbit or
goat anti-mouse; Kirkegaard & Perry Laboratories) were used
at 1:10,000 dilution.
Western Blot Analysis. Lysates were obtained as described
(35). Briefly, animals were sacrificed by cervical dislocation,
the embryosybrains immediately collected, and the different
brain regions (striatum, basal forebrain, cortex, hippocampus,
and olfactory bulb) isolated using a dissecting microscope. The
tissues were immediately frozen on dry ice. After weighing,
tissues were homogenized using a teflon glass homogenizer in
lysis buffer (10 mlymg of tissue) (10% glyceroly50 mM Tris, pH
7.5y150 mM NaCly5 mM EDTAy1 mM EGTAy1% Triton
X-100y1 mM Na3VO4y1 mM ZnCl2 in the presence of 1 mM
phenylmethylsulfonyl f luoridey10 mg/ml aprotininy5 mg/ml
leupeptin at 4°C). The extracts were passed several times
through a 1-ml insulin syringe (26 gauge), incubated for 30 min
at 4°C, and then cleared by centrifugation. Protein content was
measured by a Bio-Rad protein assay kit. Aliquots of extracts
were diluted with SDS sample buffer and boiled for 5 min.
Equal amounts of proteins were loaded onto 10% SDSyPAGE.
After transfer to nitrocellulose, the blots were blocked in 10%
nonfat dry milk in TBS-T (20 mM Tris, pH 7.5y500 mM
NaCly0.01% Tween 20) overnight at 4°C. Blots were then
incubated for 1 hr at room temperature in primary antibody.
After washing with TBS-T, membranes were exposed to
horseradish peroxidase-conjugated secondary antibody for 1
hr at room temperature. Immunoreactivities were detected
using the enhanced chemiluminescence method (Amersham)
according to the manufacturer’s instructions.
Immunoprecipitation. Injection was performed following a
procedure developed previously for embryonic transplanta-
tion of central nervous system cells (36). Ten microliters of
EGF (50 ngyml) was placed intraventricularly into E15 em-
bryos. Control embryos were injected with vehicle. Ten min-
utes after injection, embryos were removed, the telencephalic
vesicles dissected, lysed as previously described, and subjected
to immunoprecipitation as described (35). ShcA polyclonal
antibody (4 mgysample) was used. The immunoprecipitated
proteins were analyzed by Western blot analysis with the 4G10
anti-phosphotyrosine mAb or anti-Grb2 mAb.
Immunohistochemistry. Pregnant females were injected
intraperitoneally with BrdUrd (Boehringer Mannheim; 50
mgykg dissolved in saline with 0.007 M NaOH) at gestational
day 14. Injections were performed at intervals of 2 hr for a
number of periods covering the whole cell cycle duration as
estimated for that day of pregnancy. The dose of BrdUrd
employed was previously found to saturate S-labeling for at
least 2.0 hr after injection. Nuclei of the BrdUrd-containing
cells were identified as described (36–39), and adjacent sec-
tions were used for in situ hybridization with Shc and p66ShcA
probes. Injected animals were sacrificed by cervical dislocation
and embryos dissected out in ice-cold PBS, fixed for 6 hr in 4%
paraformaldehyde, and processed for paraffin embedding.
Paraffin serial sections were cut at 7 mm on a microtome,
mounted on gelatin-coated slides, and stored at 4°C, with silica
gel, until use.
In Situ Analysis. Embryos were collected from time-
pregnant outbred CD-1 female mice (Charles River Breeding
Laboratories) at E10.5–E12.5, fixed overnight in 4% parafor-
maldehyde in PBS and embedded in paraffin. Serial sections
were cut at 7 mm on a microtome, mounted on gelatin coated
slides, and stored at 4°C, with silica gel, until use. Brains from
older animals were dissected out (E16.5, E18.5, and postnatal),
fixed overnight in 4% paraformaldehyde in PBS, put in a 20%
sucrose gradient overnight at 4°C, then in OCT embedding
compound (Tissue-Tek), frozen in liquid nitrogen, and stored
at 270°C until use. Serial sections (10 mm) were cut on a
cryostat and mounted on gelatin-coated slides, washed in PBS
twice, dehydrated in ethanol, and stored at 270°C until use.
When different probes were compared, adjacent series were
used. Two alternative series were used for each probe. Paraffin
sections were dewaxed, rehydrated in ethanol, and processed
for in situ hybridization as described by Wilkinson (40) and
with minor modifications from Gulisano et al. (41). Cryostate
sections were rehydrated and processed for in situ hybridiza-
tion as described by Simmons et al. (42) and with minor
modifications from Gulisano et al. (41). Autoradiography was
performed with Kodak NTyB2 emulsion. Exposure times were
between 5 and 12 days. After development, sections were
counterstained with cresyl violet, mounted in DPX (Sigma),
and photographed using either a stereomicroscope (Zeiss
SV11) or an optical microscope (Zeiss Axiophot), with both
dark- and bright-field illumination.
Shc and P66 sense and antisense [35S]-labeled RNA probes
were synthetically produced using a 470-nt EcoRI–EcoRI
fragment cloned in pGEM3 (Promega) (7) and a 370-nt
EcoRI–EcoRI fragment cloned in pCRII (Invitrogen), respec-
tively, as templates. Transcription reactions with T7 or SP6
polymerase (Riboprobe Kit, Promega) were carried out in the
presence of [35S]CTP (Amersham) on linearized plasmids. The
probes were resuspended at a working concentration of 1 3 105
cpmyml in hybridization mix and stored at 280°C until use.
Densitometric Analysis. The relative density of immunore-
active bands on Western blots was calculated from the area of
the peak corresponding to the selected band following acqui-
sition of the blot image through a Nikon CCD video camera
module and analysis by means of the IMAGE 1.52 program
(Wayne Rasband, National Institutes of Health, Research
Services Branch, National Institute of Mental Health, Be-
thesda). Normalization over protein load was achieved by
dividing each individual peak area by the corresponding peak
area of the a-tubulin signal.
RESULTS
ShcA Expression During Neurogenesis in the Embryonic
Murine Brain. In an initial attempt to identify the intracellular
mechanisms implicated in the responses to mitogenic and differ-
entiative signals in neuroblasts, we analyzed whether ShcA pro-
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teins were expressed in the rodent forebrain at early stages of
development. Western blot analyses, performed on lysates ob-
tained from striatum, hippocampus, basal forebrain, and cortex
revealed that p46shcA, p52shcA, and p66shcA were all present at high
levels at the first gestational day analyzed (rat embryonic day 14,
E14, for striatum, basal forebrain, and cortex; E18 for hippocam-
pus) (Fig. 1A). At this embryonic stage, the majority of the cells
are still immature and proliferating actively (43). When later
developmental stages were considered (E18, P2) a sharp reduc-
tion in ShcA protein levels was observed in all of the brain regions
analyzed. In Fig. 1B, the relative densities of the immunoreactive
bands are plotted after normalization over an a-tubulin signal,
used as an internal standard. Expression of all three ShcA
isoforms decreases homogeneously during development. At all
stages considered, the relative expression levels of the three
isoforms were as follows: p52shcA . p46shcA . p66shcA. Identical
results were obtained when analyzing tissues of mouse origin
(data not shown).
ShcA Expression Declines During in Vitro Neuronal Differ-
entiation. To correlate the observed reduction in ShcA levels
with the acquisition of a differentiated state, cells from the E14
rat striatum primordia were isolated and allowed to differen-
tiate in vitro (34, 44). Previous reports showed that when
exposed to serum-free conditions (SFM) the majority of the
E14 striatal cells develop into neurons within 7 days (34, 44).
Lysates from primary striatal cells cultured for 6, 96, and 168
hr (7 days) in SFM express progressively reduced levels of
ShcA proteins (Fig. 1C). The relative densities of the immu-
noreactive bands are plotted after normalization over an
a-tubulin signal. The correlation of the in vivo and in vitro
findings of a reduced expression of ShcA proteins in coinci-
dence with cell differentiation suggests that ShcA proteins may
be of fundamental importance at early stages of neurogenesis,
when there is an enhanced proliferation of the neuroblasts
lining the lumen of the neural tube.
ShcA mRNAs Are Localized Within the Ventricular Zone
(VZ). When expression of the mRNAs encoding for the three
ShcA isoforms was analyzed at different developmental stages,
a strong hybridization signal along the entire neural tube in
E10.5 mouse embryos was revealed with two different anti-
sense riboprobes, one recognizing all three mRNAs tran-
scribed from the ShcA gene (ShcA riboprobe), the other
specific for p66 (p66shcA riboprobe) (Fig. 2 A and B). At this
stage, proliferation was exclusive to the proencephalon wall. At
E12.5 (Fig. 2 D and E), actively proliferating structures like the
ganglionic eminences and the VZ of the cortex (arrowheads)
were still highly positive for ShcA and p66shcA. On the other
hand, post mitotic areas (arrows) showed no detectable hy-
bridization signal. Outside the brain the hybridization signal
appeared to be stronger and widespread (Fig. 2, asterisks),
consistent with the literature data that indicate a ubiquitous
expression pattern of ShcA in extraneuronal tissues (20, 24–
28). At later stages (e.g., P2) mRNA expression became
restricted to the extremely small proliferative zone of the
cerebral hemisphere and the striatum (arrowheads in Fig. 2
G–I). Northern analyses confirmed a reduced presence of
ShcA mRNAs in the postnatal rat brain (not shown). In situ
hybridization assay performed with P66 and Shc sense probes
gave no specific signal (not shown).
To correlate the expression of ShcA and p66shcA mRNAs with
cell proliferation in the VZ, we used BrdUrd incorporation
followed by immunohistochemistry (37, 38). BrdUrd is incorpo-
rated by all cells that are in the S-phase of the cell cycle at the time
of the injection. Coronal sections of E14.5 brains showed ShcA
and p66shcA mRNAs (Fig. 3 A and B) in the VZ, where the
majority of the BrdUrd-labeled cells were located (Fig. 3C).
Expression of ShcA Proteins in the Adult Nervous System Is
Uniquely Localized to the Olfactory Epithelium. In a manner
consistent with our data showing selective expression of ShcA in
the proliferating neuroblasts, lysates from different regions of the
adult brain presented a barely detectable amount of ShcA pro-
teins (Fig. 4). Instead, lysates obtained from the adult olfactory
epithelium, a structure where neuronal cell renewal is also known
to occur in adult life (45), showed levels of ShcA proteins
comparable to those observed in all of the other brain regions
analyzed during early embryonic stages (Fig. 4).
Grb2 Is Constantly Expressed Throughout Neurogenesis. In
addition to associating with activated receptor tyrosine ki-
nases, phosphorylated ShcA proteins have been shown to form
complexes with the Grb2 adaptor molecule in different cellular
systems in response to specific stimuli (5, 6, 10). Grb2 adaptor
protein is known to interact with activated TK receptors
directly or through ShcA. The finding that ShcA was devel-
opmentally regulated prompted us to analyze whether Grb2
was expressed in the rodent forebrain at different development
stages. Western blot analyses, performed on homogenates
obtained from striatal tissue at different gestational days,
showed constant levels of Grb2 protein all throughout neuro-
genesis (Fig. 5). The same results were obtained using tissue
homogenates from cortex, hippocampus, and basal forebrain
taken at different stages of neurogenesis (data not shown).
FIG. 1. Expression of ShcA proteins during forebrain maturation.
(A) Western blot analyses showing maximal expression of the three
ShcA isoforms at early developmental stages in different brain regions.
Equal amounts of protein (50 mg per lane) were electrophoresed.
(Lower) Membranes were stripped and immunodecorated with anti-
a-tubulin antibody. Lysates derived from Rat-2 fibroblasts were used
as positive controls. E, embryonic; P, postnatal. (B) Densitometric
analyses of p66ShcA, p52ShcA, and p46ShcA immunoreactive bands,
normalized over a-tubulin content. Values are expressed as arbitrary
units. In all brain regions and at all time points considered, p52ShcA .
p46ShcA . p66ShcA. (C) Cell lysates were obtained from undifferen-
tiated (6 hr) and differentiated primary neuronal cultures (96 and 168
hr) generated from the E14 rat striatum primordia and grown in
serum-free conditions, allowing the cells to differentiate into neurons.
Ninety micrograms of protein were loaded and immunoblotted with
anti-ShcA. The immunoreaction to a-tubulin was used as an internal
standard. As in B, the relative densities of the immunoreactive bands
are plotted after normalization over a-tubulin content and the values
expressed in arbitrary units. Data shown were from one of three sets
of experiments, all generating the same results.
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In Vivo Functional Activation of Embryonic ShcA Proteins.
To investigate whether ShcA proteins in the VZ were subjected
of being activated, we analyzed the extent of induced ShcA
phosphorylation following injection of specific polypeptide
growth factors into the cerebral ventricular system of rat
embryos at 15 gestational days (36). Lysates from EGF-treated
and untreated (control) animals were subjected to immuno-
precipitation with anti-ShcA antibodies, followed by Western
blot analysis with anti-phosphotyrosine antibodies. Fig. 6
shows a basal level of p52shcA phosphorylation in lysates from
control animals. These data may reflect ShcA activation by
endogenous stimuli (mitogens andyor differentiative factors).
On the other hand, when an equal amount of lysed telence-
phalic material obtained from EGF-injected embryos was
subjected to the same immunoprecipitation procedure, p52shcA
phosphorylation was strongly induced (Fig. 6A). In Fig. 6B, the
same membrane filter as in A was stripped and reacted with
anti-ShcA mAb. As shown (arrows), ShcA proteins were
immunoprecipitated to the same extent in control and treated
groups. The finding of in vivo EGF-induced p52shcA phosphor-
ylation is further substantiated by the presence of a 170-kDa
phosphorylated band in the EGF-treated lane (Fig. 6A, ar-
row), which we found to react with a mAb against the EGF
receptor (EGFR), which is known to coprecipitate with phos-
phorylated ShcA proteins (not shown) (20). Furthermore,
since the activated ShcA proteins normally interact with the
FIG. 2. ShcA and p66ShcA localization in mouse sagittal sections. ShcA (A, D, and G) and p66ShcA (B, E, and H) expression in mouse sagittal
sections. Anterior is to the left. (A–C) E10.5, (D–F) E12, (G–I) P2. Bright-field views of sections counterstained with cresyl violet are also shown
(C, F, and I). Both ShcA and p66ShcA showed developmentally regulated hybridization signal exclusively in the brain. Their patterns of expression
appeared to be temporally regulated and practically coincide with the proliferative epithelium (ventricular zone, VZ) all throughout development
(arrowheads). p66ShcA mRNA was expressed in all territories showing the ShcA signal, although to a lesser extent as expected from the relative
levels of the three isoforms. Postmitotic regions (arrows) showed no specific hybridization signal. On the contrary, outside the brain Shc and p66shcA
expression patterns appear to be both ubiquitous and homogenous (asterisks in D–F). Sense probes gave no specific hybridization signals (data not
shown). Cx, cortex; Mes, mesencephalon; My, myelencephalon; Rh, rhombencephalon; Te, telencephalon.
FIG. 3. ShcA and p66ShcA expression in developing mouse cortex.
ShcA (A) and p66ShcA (B) expression in adjacent coronal sections of
the developing mouse cortex at E14.5. (C) BrdUrd antibody staining
after a 15-hr BrdUrd labeling. Both ShcA and p66ShcA expression
patterns correlated with the position of the proliferative epithelium in
the developing cortex, as revealed by BrdUrd labeling. CP, cortical
plate; VZ, ventricular zone
FIG. 4. ShcA expression in different adult brain regions and in the
olfactory epithelium. Western blot analyses showed low levels of
expression in all brain regions. p66 was the only isoform present at a
low, although detectable, level. On the other hand, in the olfactory
epithelium all three isoforms were strongly expressed and exhibited the
same relative proportional abundance as found in brain regions at
early developmental stages.
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Grb2 adaptor protein and we found Grb2 to be present
constantly throughout development, we evaluated the pres-
ence of Grb2 in lysates from control and EGF-stimulated
groups that had been subjected to immunoprecipitation with
anti-ShcA antibodies. As shown in Fig. 6C, the 23-kDa Grb2
protein coprecipitates with anti-ShcA antibodies in lysates
from treated embryos.
DISCUSSION
Several previous studies have suggested a ubiquitous expres-
sion of ShcA adaptor proteins in different nonneuronal cell
types, independent of the stage of maturation of the tissue
considered, where they act as key regulators of cell respon-
siveness to extracellular signals. In this paper, however, we
found that in the mammalian brain ShcA expression is strictly
regulated both temporally and spatially during embryonic
development.
Surprisingly, we found that the pattern of expression of this
adaptor protein correlates with the proliferative and early
differentiative events that occur in the brain, supporting the
hypothesis that ShcA proteins may have an important role in
neural development. This finding was further confirmed by in
vitro studies demonstrating a reduced level of expression of
ShcA isoforms during neuronal differentiation.
To establish a direct correlation between the presence of ShcA
and brain neurogenesis, we examined the localization of ShcA
mRNAs at different developmental stages. It is known that
during brain development active proliferation of neuroblasts
occurs in an anatomically defined and highly organized layer
lining the lumen of the neural tube, called the VZ (46). Subse-
quently, at given intervals and depending on the species consid-
ered, these cells differentiate into neurons following spatially
defined gradients of neurogenesis, which are specific for each
brain region. In the mouse cortex, for example, this phenomenon
starts at E11 (47, 48) and the first postmitotic cells migrate away
from the lumen forming the so-called cortical plate, which will
later give rise to the mature six-layered cerebral cortex (43). A
similar temporally regulated and spatially defined departure of
postmitotic cells from the VZ is also known to occur in other
brain regions (49, 50).
Our analyses showed that, in the brain, expression of ShcA
adaptor proteins is exclusively restricted to the VZ, where they
are susceptible to activation by stimulation with exogenous
factors. With the occurrence of cell differentiation, a change in
the levels of ShcA proteins occurs. In fact, in the postnatal
brain, ShcA mRNA expression remains confined to the sub-
ependymal layer lining the ventricular system. In the adult
brain, the three ShcA isoforms are only faintly detectable. This
finding is in agreement with recent reports that found low
levels of expression of ShcA in total mouse brain extracts (32,
33). Interestingly, we found that ShcA proteins remain strongly
expressed in the adult olfactory epithelium in which neuronal
cell renewal occurs throughout life. All these phenomena were
peculiar to ShcA. In fact, when the presence of another adaptor
protein, Grb2, was assessed, no particular changes in expres-
sion levels were observed during neurogenesis. These data,
therefore, argue in favor of an important role for ShcA at the
transition from proliferation to differentiation in the brain.
These findings indicate that (i) ShcA adaptor proteins are
subjected to strict developmental control, their expression
being associated with the proliferative events of the developing
mammalian forebrain and adult olfactory epithelium and (ii)
the mRNAs that give rise to the three ShcA isoforms are
expressed in a spatially restricted manner and confined to an
anatomically defined region of the developing brain, i.e., the
germinal epithelium, a transitory structure known to include
the population of proliferating neuroblasts.
These data support the hypothesis that important variations
in ShcA levels during neurogenesis may change the responses
of a particular cell type to external stimuli. Loss of ShcA during
neurogenesis may guarantee a cell from undesired prolifera-
tion, andyor may represent the major force that drives neu-
roblasts from proliferation into differentiation.
In mature brain cells, the Ras signaling pathway may be
activated by proteins different from ShcA. In this respect, the
two recently isolated Shc proteins, ShcB and ShcC, have been
found to be expressed in total extracts from the adult brain (32,
33) and our preliminary data indicate that their expression
levels increase in association with the decrease in ShcA protein
levels during development (E.C., unpublished work).
We found that ShcA proteins expressed in neuroblasts can
be activated, since after EGF injection into the cerebral
ventricular system of rat embryos at 15 gestational days, an
increased phosphorylation of p52shcA isoform was detected by
immunoprecipitation and Western blot analyses. Other in vitro
investigations have reported a similar prevalence of phosphor-
ylated p52shcA in stimulated cells (20, 24–28). We focused on
EGF since (i) this molecule shares, with other growth factors,
the ability to elicit proliferation of immature mammalian
central nervous system progenitor cells (1–3, 51–55) and (ii) in
nonneuronal cellular systems activation of its corresponding
surface receptor has been shown to induce ShcA phosphory-
lation (11, 20, 24–29). Furthermore, in addition to associating
with activated receptor tyrosine kinases, phosphorylated ShcA
FIG. 5. Expression of Grb2 protein during neurogenesis. (Right)
Western blot analysis showing Grb2 protein levels in lysates from
striatum. Constant levels of expression were found. Samples and
membranes were treated as described in Fig. 1.
FIG. 6. p52ShcA was phosphorylated and interacted with Grb2 in
the embryonic telencephalic vesicles following intraventricular injec-
tion of EGF. (A) Phosphotyrosine immunoblot of ShcA immunopre-
cipitates after in vivo EGF treatment; 10 min after injection, the
embryos were removed and the telencephalic vesicles isolated and
prepared for the immunoprecipitation. Phosphorylated p52ShcA is
indicated. Control embryos were injected with vehicle. A 170-kDa
phosphorylated band (arrow) corresponding to the coprecipitated
EGF receptor is also visible in the treated group. (B) Anti-ShcA
immunoblot of the filter shown in A. The membrane was stripped and
reacted with ShcA mAb. As shown in the figure, ShcA proteins were
immunoprecipitated to the same extent in control and EGF-treated
groups. (C) Anti-Grb2 immunoblot of the same immunoprecipitates
as in A. Arrow indicates the 23-kDa Grb2 protein, which more
abundantly coprecipitates with ShcA in the treated group.
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proteins have been shown to form complexes with the Grb2
adaptor molecule in different cellular systems in response to
specific stimuli (4–6, 13, 14). To further consolidate our results
indicating ShcA recruitment in vivo in the population of
proliferating neuroblasts lining the neural tube, we showed
that Grb2 coprecipitates with the immunoprecipitated ShcA
proteins in EGF-stimulated embryonic brains.
These results, showing in vivo EGF-induced p52shcA phos-
phorylation and its association to Grb2, combined with the
data on the restricted expression of ShcA proteins in the VZ,
indicate functional activity of ShcA proteins in the embryonic
neuroepithelium.
Although we have focused mainly on ShcA contribution
from neuroblasts, proliferating glial elements populating the
brain at advanced stages of development and reactive astro-
cytes found in the adult injured brain may also express ShcA.
We believe that the findings reported here define new
modalities by which the switch between proliferation and
differentiation of immature neuroblasts may be controlled,
suggesting that differences in the levels of ShcA adaptor
proteins at different stages of the development of a brain cell
may change the pattern of protein–protein interactions in-
duced by activation of a particular membrane receptor, thereby
setting that cell to respond differently to the same extracellular
factor. From this perspective, the fact that levels of ShcA
proteins vary according to the cell state may be of particular
relevance since these proteins act as initiators of a signaling
cascade that links growth factor polypeptides to nuclear events.
The possibility that cells that have to escape from the VZ
might modify their adaptor proteins such that the extracellular
interactions will promote cell migrationydifferentiation rather
than preventing it, andyor activate new genes in the cascade of
differentiation, remains an intriguing possibility.
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